Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.

被引：0
|
作者：
Fowler, Nathan Hale
Samaniego, Felipe
Jurczak, Wojciech
Lech-Maranda, Ewa
Ghosh, Nilanjan
Patten, Piers
Reeves, James Andrew
Leslie, Lori Ann
Chavez, Julio C.
Ghia, Paolo
Tarella, Corrado
Burke, John M.
Sharman, Jeff Porter
Kolibaba, Kathryn
O'Connor, Owen A.
Cheah, Chan
Miskin, Hari P.
Sportelli, Peter
Weiss, Michael S.
Zinzani, Pier Luigi
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Jagiellonian Univ, Dept Hematol, Krakow, Poland
[4] Ctr Postgrad Med Educ, Inst Hematol & Transfus Med, Dept Hematol, Warsaw, Poland
[5] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[6] Kings Coll Hosp London, London, England
[7] Sarah Cannon Res Inst, Florida Canc Specialists South, Ft Myers, FL USA
[8] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[10] Univ Vita Salute San Raffaele, Milan, Italy
[11] IRCCS San Raffaele Sci Inst, Milan, Italy
[12] AO Ordine Mauriziano Umberto I, Div Univ Ematol & Terapie Cellulari, Turin, Italy
[13] Rocky Mt Canc Ctr, Aurora, CO USA
[14] Willamette Valley Canc Inst & Res Ctr, US Oncol Res, Eugene, OR USA
[15] US Oncol Res, Compass Oncol, Vancouver, WA USA
[16] Columbia Univ, Med Ctr, New York, NY USA
[17] Sir Charles Gairdner Hosp, Ctr Comprehens Canc, Nedlands, WA, Australia
[18] TG Therapeut Inc, New York, NY USA
[19] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7506
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients With Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open Label, Registration Directed Phase II Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 9 - 11
  • [2] Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open-label, registration directed Phase II study
    Fowler, Nathan H.
    Samaniego, Felipe
    Jurczak, Wojciech
    Lech-Maranda, Ewa
    Ghosh, Nilanjan
    Anz, Bertrand
    Patten, Piers
    Reeves, James A.
    Leslie, Lori A.
    Smolewski, Piotr
    Chavez, Julio C.
    Ghia, Paolo
    Tarella, Corrado
    Burke, John M.
    Sharman, Jeff
    Kolibaba, Kathryn
    O'Connor, Owen A.
    Cheah, Chan Y.
    Miskin, Hari P.
    Sportelli, Peter
    Weiss, Michael S.
    Zinzani, Pier Luigi
    CANCER RESEARCH, 2019, 79 (13)
  • [3] Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study
    Noy, Ariela
    de Vos, Sven
    Thieblemont, Catherine
    Martin, Peter
    Flowers, Christopher
    Morschhauser, Franck
    Collins, Graham P.
    Ma, Shuo
    Coleman, Morton
    Peles, Shachar
    Smith, Stephen
    Smith, Alina
    Munneke, Brian
    Dimery, Isaiah
    Beaupre, Darrin
    Chen, Robert W.
    BLOOD, 2016, 128 (22)
  • [4] Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
    Song, Yuqin
    Song, Yongping
    Liu, Lihong
    Zhang, Mingzhi
    Li, Zhiming
    Ji, Chunyan
    Xu, Wei
    Liu, Ting
    Xu, Bing
    Wang, Xin
    Gao, Sujun
    Zhang, Huilai
    Hu, Yu
    Li, Yan
    Cheng, Ying
    Yang, Haiyan
    Cao, Junning
    Zhu, Zunmin
    Hu, Jianda
    Zhang, Wei
    Jing, Hongmei
    Ding, Kaiyang
    Lu, Zhengguang
    Zhang, Bin
    Zhao, Renbin
    Xu, Zhixin
    Zhu, Jun
    BLOOD, 2019, 134
  • [5] Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study
    Deng, Lijuan
    Li, Zhiming
    Zhang, Huilai
    Huang, Haiwen
    Hu, Jianda
    Liu, Lihong
    Liu, Ting
    Jin, Jie
    Zhu, Zunmin
    Li, Wenyu
    Huang, Zhenqian
    Huang, Wenrong
    Zhou, Keshu
    Yang, Haiyan
    Zhang, Mingzhi
    Ding, Kaiyang
    Zhou, Hui
    Hu, Yu
    Shuang, Yuerong
    Cao, Junning
    Gao, Sujun
    Li, Dengju
    Sun, Zimin
    Zhang, Qingyuan
    Yi, Shuhua
    Ji, Chunyan
    Zhang, Liansheng
    Hou, Cheng
    Du, Yue
    Wang, Weige
    Zhao, Renbin
    Song, Yuqin
    Zhu, Jun
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (11) : 1742 - 1750
  • [6] Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
    Song, Yuqin
    Song, Yongping
    Liu, Lihong
    Zhang, Mingzhi
    Li, Zhiming
    Ji, Chunyan
    Xu, Wei
    Liu, Ting
    Xu, Bing
    Wang, Xin
    Gao, Sujun
    Zhang, Huilai
    Hu, Yu
    Li, Yan
    Cheng, Ying
    Yang, Haiyan
    Cao, Junning
    Zhu, Zunmin
    Hu, Jianda
    Zhang, Wei
    Jing, Hongmei
    Ding, Kaiyang
    Lu, Zhengguang
    Zhang, Bin
    Zhao, Renbin
    Xu, Zhixin
    Zhu, Jun
    BLOOD, 2020, 136
  • [7] An open label, single arm, multicenter phase II study of the efficacy and safety of LP-168 monotherapy for relapsed or refractory mantle cell lymphoma.
    Song, Yuqin
    Tang, Xiaoqiong
    Cai, Qingqing
    Liu, Lihong
    Jing, Hongmei
    Jiang, Ming
    Sun, Xiuhua
    Wu, Jianqiu
    Yang, Yu
    Wu, Huijing
    Peng, Zhigang
    Ding, Kaiyang
    Yi, Shuhua
    Yan, Xiaojing
    Wu, Guowu
    Wu, Yudan
    Cui, Jie
    Ou, Pengju
    Tan, Fenlai
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma
    Panayiotidis, Panayiotis
    Follows, George A.
    Mollica, Luigina
    Nagler, Arnon
    Ozcan, Muhit
    Santoro, Armando
    Stevens, Don
    Trevarthen, David
    Hiemeyer, Florian
    Garcia-Vargas, Jose
    Childs, Barrett H.
    Zinzani, Pier Luigi
    Dreyling, Martin
    BLOOD ADVANCES, 2021, 5 (03) : 823 - 828
  • [9] SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY)
    Tedeschi, A.
    Trotman, J.
    Zinzani, P.
    Cavallo, F.
    Marasca, R.
    Liberati, A.
    Linton, K.
    Mckay, P.
    Hu, B.
    Coleman, M.
    Ardeshna, K.
    Bijou, F.
    Marcus, R.
    Portell, C.
    Thieblemont, C.
    Bachy, E.
    Costello, R.
    Iyengar, S.
    Mocikova, H.
    Co, M.
    Li, X.
    Zhou, W.
    Cappellini, M.
    Tankersley, C.
    Huang, J.
    Opat, S.
    HAEMATOLOGICA, 2021, 106 (10) : 35 - 35
  • [10] Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study
    Handunnetti, Sasanka M.
    Khot, Amit
    Anderson, Mary Ann
    Blombery, Piers
    Burbury, Kate
    Ritchie, David
    Hicks, Rodney J.
    Birbirsa, Besiat
    Bressel, Mathias
    Di Iulio, Juliana
    Westerman, David Alan
    Lade, Stephen
    Roberts, Andrew W.
    Seymour, John F.
    Tam, Constantine S.
    BLOOD, 2019, 134
12345